Abstract Number: 1671 • 2012 ACR/ARHP Annual Meeting
Characterization of Jo-1 Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease
Background/Purpose: Anti-Jo-1 autoantibodies (Jo-1 Abs), directed against histidine tRNA synthetase (HisRS1), are detected in a high proportion of patients with both autoimmune inflammatory myopathy (IM)…Abstract Number: 1672 • 2012 ACR/ARHP Annual Meeting
Myosin Skews Effector Immune Cells of Scurfy Mice to Target Muscles in an Adoptive Transfer Model of Myositis
Background/Purpose: Myositis is associated with an inflammatory process that results in pronounced muscle weakness and is observed in some regulatory T cell (Treg) deficient mouse…Abstract Number: 1673 • 2012 ACR/ARHP Annual Meeting
Clinical Phenotypes of Caucasian Adult and Juvenile Dermatomyositis Patients with Anti-MDA5 Autoantibodies
Background/Purpose: Autoantibodies to MDA5 have been previously reported in Japanese patients with dermatomyositis (DM) and are associated with clinically-amyopathic DM and rapidly progressing interstitial lung…Abstract Number: 1674 • 2012 ACR/ARHP Annual Meeting
Myeloid Related Proteins Induce Muscle Derived Inflammatory Mediators in Juvenile Dermatomyositis
Background/Purpose: The etiopathogenesis of Juvenile Dermatomyositis (JDM) remains poorly understood. In particular the contribution of monocytes or macrophages, which are frequently observed to be an…Abstract Number: 1675 • 2012 ACR/ARHP Annual Meeting
Myositis Autoimmunity and Muscle Weakness Are Linked to TNF-Alpha Suppression of Micrornas-1, 133, and 206 in Myoblasts and Myocytes
Background/Purpose: The molecular basis of myopathies such as dermatomyositis, polymyositis and inclusion-body myositis, which are characterized by chronic muscle inflammation followed by long term skeletal…Abstract Number: 1676 • 2012 ACR/ARHP Annual Meeting
Abatacept As First Line Biological Treatment for Severe Juvenile Idiopathic Arthritis-Related Uveitis. A Multicenter Study
Background/Purpose: Anterior uveitis is a serious complication of Juvenile Idiopathic Arthritis (JIA). Recently, Abatacept (ABA) has been used in children with JIA-uveitis who had failed…Abstract Number: 1637 • 2012 ACR/ARHP Annual Meeting
A Novel Peptide Inhibiting the Binding Between C1q and Immunoglobulin Ameliorates Joint Destruction in Rats with Collagen-Induced Arthritis
Background/Purpose: C1q is the major subcomponent of the first component of complement protein. The activation of the complement is triggered by binding of C1q to…Abstract Number: 1638 • 2012 ACR/ARHP Annual Meeting
Synovial Fibroblast Migration Is Modulated by the Focal Contact Protein Lasp-1
Background/Purpose: RA synovial fibroblasts (SF) have been suggested to contribute to the spreading of disease through their ability to leave cartilage destruction sites, migrate via…Abstract Number: 1639 • 2012 ACR/ARHP Annual Meeting
FLIP in Macrophages Promotes the Progression of Serum Transfer-Induced Arthritis
Background/Purpose: Flip is well known as an anti-apoptotic protein induced by chronic inflammation that protects against death receptor-mediated apoptosis. Employing a FLIP myeloid lineage knock-out…Abstract Number: 1640 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of 3.7 Years
Background/Purpose: Tocilizumab (TCZ)—an IL-6 receptor inhibitor—has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving physical function in rheumatoid arthritis (RA) patients (pts). This…Abstract Number: 1641 • 2012 ACR/ARHP Annual Meeting
When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Background/Purpose: Tuberculosis infection (TI) is one of the most serious adverse events related to tumour necrosis factor (TNF) antagonists. According to the current treatment guidelines…Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…Abstract Number: 1643 • 2012 ACR/ARHP Annual Meeting
Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol
Background/Purpose: Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-TNF approved in the US for the treatment of Crohn's disease (CD) and rheumatoid arthritis (RA). Pre-clinical…Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…Abstract Number: 1645 • 2012 ACR/ARHP Annual Meeting
Combination of Isoniazid for Latent Tuberculosis with Traditional and/or Biologic Disease Modifying Anti-Rheumatic Drugs Is Well Tolerated in Patients with Rheumatic Diseases
Background/Purpose: Patients with rheumatic diseases (RD) are typically treated with conventional and /or biologic disease modifying anti-rheumatic drugs (DMARD's) including tumor necrosis factor inhibitors (TNFi). …